Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Nov 14, 2014; 20(42): 15657-15663
Published online Nov 14, 2014. doi: 10.3748/wjg.v20.i42.15657
Published online Nov 14, 2014. doi: 10.3748/wjg.v20.i42.15657
Enteric microbiota leads to new therapeutic strategies for ulcerative colitis
Wei-Xu Chen, Li-Hua Ren, Rui-Hua Shi, Department of Gastroenterology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, Jiangsu Province, China
Author contributions: Chen WX wrote and reviewed the manuscript; Ren LH contributed to the work; Shi RH reviewed and assisted with editing the manuscript.
Correspondence to: Rui-Hua Shi, MD, PhD, Department of Gastroenterology, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing 210029, Jiangsu Province, China. ruihuashi@126.com
Telephone: +86-25-83674636 Fax: +86-25-83674636
Received: February 25, 2014
Revised: May 11, 2014
Accepted: June 26, 2014
Published online: November 14, 2014
Revised: May 11, 2014
Accepted: June 26, 2014
Published online: November 14, 2014
Core Tip
Core tip: The human gut is comprised of a large, diverse, and dynamic microbiota. The enteric microbiota plays an important role in regulating anti-inflammatory and immunoregulatory activities. An imbalance of the normal enteric microbiota composition, termed dysbiosis, underlies the pathogenesis of ulcerative colitis (UC). Therefore, manipulation of the dysbiosis is an attractive strategy for UC therapy. This review discusses new therapies associated with the regulation of enteric microbiota for UC patients.